The Cancer Letter

Inside information on cancer research and drug development

NCI requests $7.8B for FY2023 to increase R01 paylines to 13th percentile

In Brief

Elvan ‘Ellie’ Daniels named SVP of extramural discovery science at ACS
David Frank named director of the Division of Hematology at Emory
Gregory Lesinski named associate director for basic research at Emory
Yamilé Molina named associate director for community outreach and engagement at University of Illinois Cancer Center
Robert Mannel, Bradley Monk, Carol Aghajanian named to new positions on the GOG Foundation’s board of directors
Benjamin Ellingson receives $665,000 Idea award to improve brain tumor imaging

Drugs & Targets

Active ingredient hypericin receives FDA orphan drug designation for T-cell lymphoma
Science 37, Foundation Medicine collaborate on interventional home-based clinical trials in oncology
FDA requires monitoring of long-term clinical outcomes for robotic surgery in breast cancer
Genentech pulls TNBC indication for Tecentriq
Tibsovo receives FDA approval for advanced or metastatic cholangiocarcinoma
Opdivo receives FDA approval for adjuvant treatment of urothelial carcinoma

In The Clinic

Trials & Tribulations

Rogue drug maker first inflates the price of lomustine, then says No to Medicare coverage

Rogue drug maker first inflates the price of lomustine, then says No to Medicare coverage
Annals of Unintended Consequences: How FDA regulations undermine the biosimilar marketplace and the BPCIA
Trials & Tribulations
Precision oncology must evolve to address health disparities
FreeTrials & Tribulations
It’s time to rethink clinical trials in a post-pandemic world
Trials & Tribulations
Best practices in preventing heartbreak:
Trials & Tribulations

Latest Issue

Read the latest issue
DOWNLOAD THE PDF

UPCOMING EVENTS

There are no upcoming events

The Cancer Letter is an independent weekly news publication and the leading source for information on the issues that shape oncology.

Login

Looking for IP Login?